Selen Ezgi Cankurtaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selen Ezgi Cankurtaran has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Cemre Irmak Kayalan
Faculty of Engineering and Natural Science, Sabanci University, Istanbul 34956, Turkey
1 shared publication - Defne Hız
Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey
1 shared publication - Fatma Sert
Department of Genetics and Bioengineering, Istanbul Bilgi University, Eyupsultan, Turkey
1 shared publication - Hasan Kurt
Regenerative and Restorative Medicine Research Center (REMER) Research Institute for Health Sciences and Technologies (SABITA) Istanbul Medipol University Istanbul Türkiye
1 shared publication - Meral Yüce
SUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye
1 shared publication - Mert Gülmez
Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey
1 shared publication
Latest Publications
- Open Access
- 21 March 2022
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 90 (1) , 21
Temperature and pH-Dependent Behaviors of mAb Drugs: A Case Study for Trastuzumab
The distortions in the high-order structure of therapeutic monoclonal antibodies (mAbs) under different environmental conditions acutely affect mAb stability, resulting in altered safety, efficacy, and shelf-life profiles. The overall stability of mAbs depends on many factors, and it requires complementary techniques for an in-depth analysis. The stability of mAbs can be characterized by differential centrifugal sedimentation (DCS), differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF), and size exclusion chromatography (SEC) techniques. In this report, temperature-ramped dynamic light scattering (DLS), and circular dichroism (CD) spectroscopy were employed as complementary tools to show how temperature and pH affect the aggregation of a model mAb, trastuzumab, in solution. The results showed that the aggregation onset temperature of trastuzumab defined by DLS was 75 °C, which decreases the amount of β-sheets and causes a slight increase in helix structures. Moreover, the melting temperature of trastuzumab was determined to be between 80–83 °C by temperature-ramped CD spectrophotometry, which is in line with the Tm of trastuzumab’s Fab region tested with DSC. Thus, unfolding and aggregation of trastuzumab start simultaneously at 75 °C, and unfolding triggers the aggregation. The temperature-ramped CD and DLS methods are robust tools to determine the thermal behavior of biosimilars in various solution conditions. Their complementary usage provides solid scientific background for regulatory applications and a better understanding of mAb instability and its relationship with structural changes.
- 21 March 2022
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 90 (1) , 21
Open AccessTemperature and pH-Dependent Behaviors of mAb Drugs: A Case Study for Trastuzumab
The distortions in the high-order structure of therapeutic monoclonal antibodies (mAbs) under different environmental conditions acutely affect mAb stability, resulting in altered safety, efficacy, and shelf-life profiles. The overall stability of mAbs depends on many factors, and it requires complementary techniques for an in-depth analysis. The stability of mAbs can be characterized by differential centrifugal sedimentation (DCS), differential scanning calorimetry (DSC), differential scanning fluorimetry (DSF), and size exclusion chromatography (SEC) techniques. In this report, temperature-ramped dynamic light scattering (DLS), and circular dichroism (CD) spectroscopy were employed as complementary tools to show how temperature and pH affect the aggregation of a model mAb, trastuzumab, in solution. The results showed that the aggregation onset temperature of trastuzumab defined by DLS was 75 °C, which decreases the amount of β-sheets and causes a slight increase in helix structures. Moreover, the melting temperature of trastuzumab was determined to be between 80–83 °C by temperature-ramped CD spectrophotometry, which is in line with the Tm of trastuzumab’s Fab region tested with DSC. Thus, unfolding and aggregation of trastuzumab start simultaneously at 75 °C, and unfolding triggers the aggregation. The temperature-ramped CD and DLS methods are robust tools to determine the thermal behavior of biosimilars in various solution conditions. Their complementary usage provides solid scientific background for regulatory applications and a better understanding of mAb instability and its relationship with structural changes.